This would indicate that the engagement of a few molecules of FcγRIIIA can deliver an efficient activating signal for cytotoxicity; accordingly, short-term cytolysis of tumor targets through the humanized antibodies rituximab or trastuzumab, is not inhibited at 1 μM fluvastatin concentration and only a 50% inhibition was found at 10 μM. The gene discussed is FCGR3A; the disease is neoplasm.